← back to search

Muhammad Ishrat Husain

Royal Ottawa Mental Health Centre · CA
Area of research
Psychiatry and Mental health · Biological Psychiatry
Research interest
Research interests include Bipolar Disorder and Treatment, Tryptophan and brain disorders, Psychedelics and Drug Studies, and Treatment of Major Depression.
h-index
34
citations
5,480
works
241
NIH funding
primary concept
Medicine
email

Recent publications

A Digital Dialectical Behaviour Therapy Intervention for Acute Suicidality in Psychiatric Inpatients: A Feasibility Randomised Controlled Study: Intervention numérique en thérapie comportementale dialectique en cas de suicidabilité aiguë de patients hospitalisés en psychiatrie : Étude de faisabilité contrôlée à répartition aléatoire.
2025cited by 3position: contributordoi
Feasibility and Acceptability of Online Culturally Adapted Cognitive Behavioural Therapy for Depression and Anxiety in Canadians of South Asian Origin: A Randomized Controlled Trial: Faisabilité et acceptabilité de la thérapie cognitivo-comportementale en ligne adaptée à la culture pour traiter la dépression et l'anxiété chez les Canadiens d'origine sud-asiatique : Essai contrôlé à répartition aléatoire.
2025cited by 1position: contributordoi
A longitudinal study of changes in depressive symptoms and risk factors for congestive heart failure.
2025cited by 1position: contributordoi
Associations between structural brain measures and cognitive function in bipolar disorder: a systematic review and meta-analysis.
2025cited by 1position: contributordoi
Innovations in the Treatment of Mood Disorders: Exploring Microbiome, Digital and Culturally Adapted Approaches.
2025cited by 0position: contributordoi
Extending the Impact of Mood Disorder Care Through Treatment Optimization and Accessibility.
2025cited by 0position: contributordoi
Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.
2025cited by 0position: contributordoi
A randomised controlled feasibility trial comparing culturally adapted psychoeducation and treatment as usual for persons with bipolar disorders in Nigeria.
2025cited by 0position: contributordoi
The effect of the quality of the national health security systems in 12 countries on the prevalence of suicide crisis syndrome during the COVID-19 pandemic.
2025cited by 0position: contributordoi
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes
The Canadian Journal of Psychiatry 2024cited by 271position: middledoi
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.
2024cited by 177position: contributordoi
Mental health and psychosocial interventions in the context of climate change: a scoping review
npj Mental Health Research 2024cited by 63position: middledoi
Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.
2024cited by 8position: contributordoi
Prescribed psychostimulants and other pro-cognitive medications in bipolar disorder: A systematic review and meta-analysis of recurrence of manic symptoms.
2024cited by 4position: contributordoi
Associations between C-reactive protein and individual symptoms of depression in a lower-middle income country.
2024cited by 3position: contributordoi
A History of Suicide Attempt Is Associated with Increased Sympathetic Activation in Bipolar Disorder.
2024cited by 3position: contributordoi
Challenges in defining treatment-resistant mania in adults: A systematic review.
2024cited by 2position: contributordoi
Mood regulation in euthymic patients with a history of antidepressant-induced mania.
2024cited by 1position: contributordoi
Neural effects of psychedelics: Complexity the key word.
2024cited by 0position: contributordoi
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
2023cited by 109position: contributordoi
Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms.
2023cited by 93position: contributordoi
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
2023cited by 72position: contributordoi
Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.
2023cited by 37position: contributordoi
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
2023cited by 36position: contributordoi
Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.
2023cited by 26position: contributordoi
Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
2023cited by 21position: contributordoi
Culturally Adapted Cognitive Behaviour Therapy (CaCBT) to Improve Community Mental Health Services for Canadians of South Asian Origin: A Qualitative Study
The Canadian Journal of Psychiatry 2023cited by 17position: contributordoi
Ketamine for bipolar depression: an updated systematic review.
2023cited by 15position: contributordoi
Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.
2023cited by 13position: contributordoi
Cross-national presence and sociodemographic correlates of the suicide crisis syndrome.
2023cited by 12position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Benoit H. Mulsant · Canada Research Chairs35 papers (2020–2025) · 27 papers (2020–2025)Allan H. Young · King's College Hospital11 papers (2019–2024)Brett D.M. Jones · Centre for Addiction and Mental Health9 papers (2020–2025) · 8 papers (2021–2025)Allan H. Young · Kingsley House8 papers (2017–2020)David Castle · Tasmanian Land Conservancy7 papers (2022–2025)John Hodsoll · King's College London6 papers (2020–2024)Paul Bassett · Amersham Hospital6 papers (2019–2021)Paul Kurdyak · Western University6 papers (2019–2023)Andre F Carvalho · Institut d'Investigacions Biomèdiques de Barcelona6 papers (2020–2021)Andre R Brunoni · Canadian Journal of Communication (Canada)6 papers (2020–2022)Stefan Kloiber · Canada Research Chairs5 papers (2020–2023)Zafiris J. Daskalakis · Centre for Addiction and Mental Health5 papers (2020–2022)André F. Carvalho · Barwon Health5 papers (2018–2022)Michaël Maes · Institute of Electronics and Computer Science5 papers (2018–2022)Brett D. M. Jones · Centre for Addiction and Mental Health4 papers (2020–2022)Abigail Ortiz · The University of Texas Southwestern Medical Center4 papers (2024–2025)Daniel M. Blumberger · Institut Universitaire en Santé Mentale de Québec4 papers (2022–2025)Imran B. Chaudhry · University of Manchester4 papers (2017–2020)